3.8 Graft Failure Classification & Donor Chimerism Tracking
Key Takeaways
- Primary and secondary graft failure are defined with platform-specific timing and count/chimerism criteria; urgent workup includes marrow, product, infection, drug, immune and relapse causes.
- Donor chimerism analysis via Short Tandem Repeat PCR (STR-PCR) or another validated assay identifies complete, mixed, or changing lineage-specific chimerism.
- Lineage-specific chimerism matters more than a single whole-blood value, because T-cell and myeloid compartments can diverge and carry different implications for relapse and graft dysfunction.
- A declining donor chimerism trend triggers confirmation and evaluation for relapse, graft dysfunction, infection, and treatment effects before the team considers immunosuppression adjustment, DLI, or disease-directed therapy.
- Therapeutic rescue options for graft failure - including stem-cell boost, re-conditioning and second transplant, or growth-factor support - are chosen from the underlying cause and the transplant platform, not from the count threshold alone.
1. Graft Failure: Classification, Etiology & Management
The 2024 harmonized definitions distinguish delayed recovery, poor graft function, graft failure, and rejection. For peripheral-blood or marrow grafts, primary graft failure is absence of ANC recovery to at least 500/mcL by day +30 with associated pancytopenia; for cord blood the time point is day +42. Secondary graft failure is a decline in hematopoietic function requiring support after prior recovery. Poor graft function describes inadequate counts despite donor chimerism and requires exclusion of relapse, infection, drugs, immune destruction, and other causes.
Chimerism measures donor-versus-recipient hematopoiesis; it is not itself minimal residual disease. Harmonized terminology describes full donor chimerism as greater than 95%, mixed chimerism as 5%–95%, and absent donor chimerism as less than 5% in the tested compartment. Interpret lineage, assay, trajectory, disease, transfusion, and timing. Evaluate marrow morphology/cellularity, disease/MRD by validated disease assay, infection, medications, DSA where relevant, and donor chimerism before selecting treatment.
Therapeutic Rescues for Graft Failure
- Hematopoietic support: Growth factor, thrombopoietin-receptor agonist, cell boost or other support is selected only after the team evaluates graft source, marrow, infection, relapse, immune injury, drugs and organ function; dosing is protocol-specific.
- CD34-positive selected stem-cell boost: A cryopreserved or newly collected product from the original donor may be given without conditioning in selected poor-graft-function cases. T-cell depletion reduces but does not abolish GVHD and other infusion risks, and response varies by cause, cell dose, infection, and marrow status.
- Second Allogeneic Transplant: Required for refractory primary graft rejection, utilizing a new donor (e.g., haploidentical or cord blood) with a conditioning regimen aimed at overcoming host alloimmunization.
2. Donor Chimerism Analysis & Clinical Interpretation
Chimerism testing estimates the relative proportion of donor-derived and recipient-derived hematopoietic or immune cells after allogeneic transplant. It documents donor/recipient hematopoiesis and can complement surveillance, but it does not identify a malignancy clone and cannot replace disease-specific measurable residual disease (MRD) testing.
Chimerism Testing Methodologies
- Short Tandem Repeat PCR (STR-PCR): The gold-standard molecular technique. Analyzes highly polymorphic, repetitive non-coding DNA loci unique to donor and recipient genomes. Highly sensitive, detecting recipient DNA down to $1%\text{ to }5%$.
- Fluorescent In Situ Hybridization (FISH) for Sex Chromosomes: Utilized in sex-mismatched donor-recipient pairs (e.g., female donor to male recipient, detecting XX vs XY chromosomes). Evaluates single-cell nuclear morphology under fluorescence.
- Next-Generation Sequencing (NGS) Chimerism: Ultra-high sensitivity testing capable of detecting micro-chimerism down to $<0.1%$, providing earliest detection of impending relapse.
Chimerism Classifications
+---------------------------------------------------------------------------------------------------+
| CHIMERISM CLASSIFICATION STATES |
| |
| 1. COMPLETE DONOR CHIMERISM (Full Engraftment): |
| * >= 95% to 100% of analyzed cells are of DONOR origin. |
| * Describes a predominantly donor-derived sample; it does not by itself prove disease remission. |
| |
| 2. MIXED CHIMERISM (MC): |
| * Coexistence of donor and recipient hematopoiesis (often about 5% to 95% donor cells). |
| * Frequently observed and acceptable following Reduced-Intensity (RIC) or Non-Myeloablative |
| (NMA) conditioning in early months, but should steadily convert toward full donor. |
| |
| 3. FALLING / DECLINING DONOR CHIMERISM: |
| * Progressive decrease in donor cell percentage on serial testing (e.g., 98% -> 85% -> 65%). |
| * A reproducible trend that requires correlation for graft instability, relapse, or expected platform effects. |
+---------------------------------------------------------------------------------------------------+
Lineage-Specific Chimerism: T-Cell vs Myeloid
Whole-blood chimerism can obscure subtle lineage-restricted failure. Flow-cytometric immunomagnetic bead cell sorting isolates specific peripheral blood cell fractions for separate STR-PCR analysis:
- $\text{CD3}^+$ T-Lymphocyte Chimerism:
- Measures the donor immune system and alloreactive T-cell compartment.
- Controls graft rejection, graft-versus-host disease (GVHD), and graft-versus-leukemia (GVL) effect.
- A reproducible drop in $\text{CD3}^+$ donor chimerism may signal graft instability, but meaning depends on timing, conditioning and the T-cell-modulation platform.
- $\text{CD33}^+ / \text{CD15}^+$ Myeloid & Neutrophil Chimerism:
- Measures bone marrow hematopoietic stem cell production and myeloid precursors.
- In AML or MDS, falling myeloid donor chimerism can raise concern for relapse, but it requires confirmation and correlation with disease-specific MRD, marrow findings and counts.
Clinical Interpretation and Response to Declining Donor Chimerism
A single percentage is not a diagnosis. Confirm an unexpected result and interpret its trend, lineage, assay sensitivity, conditioning platform, disease, post-transplant day, and concurrent MRD. Evaluate marrow morphology, counts, medications, infection/reactivation, GVHD, and graft function. Falling myeloid chimerism may raise concern for relapse in a myeloid malignancy but is not itself proof; falling T-cell chimerism may have a different meaning after reduced-intensity or T-cell-modulated approaches.
Possible responses include observation with closer testing, treating infection or medication toxicity, adjusting immunosuppression, disease-directed therapy, a CD34-positive stem-cell boost, DLI, or another transplant. Immunosuppression taper is individualized because an abrupt change can provoke GVHD, and DLI can cause GVHD or marrow aplasia and is not suitable for every disease or platform. The nurse verifies the planned intervention, monitors counts/chimerism/MRD together, and teaches that the goal is safe donor hematopoiesis and disease control—not an automatic “100%” number at any cost.
3. Stem Cell Boost Versus Second Transplantation
When graft function is inadequate, two rescue strategies exist, and they answer different questions.
A CD34-selected stem cell boost delivers additional donor stem cells from the original donor without repeat conditioning. Because the product is CD34-selected, its T-cell content is minimized to limit GVHD risk. It is used when the marrow needs more stem cells but the graft has not been immunologically rejected, and it requires that the original donor be available and able to donate again. Avoiding conditioning makes it far better tolerated in a patient who is already cytopenic and infected.
A second transplant delivers new conditioning plus a graft, from the same or a different donor. It is used when rejection is immunologic, when the original donor is unavailable, or when disease has recurred. It is substantially more toxic and is undertaken in a patient with limited reserve, so donor search, organ assessment, and goals-of-care discussion all restart.
Nursing preparation differs accordingly. A boost is often arranged quickly and needs donor coordination, product scheduling, and infection control through continued aplasia. A second transplant requires full re-evaluation and re-consent, and the conversation about cumulative toxicity and realistic outcomes is one the patient and family need time and support to have.
A 45-year-old patient who achieved full neutrophil and platelet engraftment on Day +15 post-allogeneic transplant develops severe pancytopenia on Day +28 (ANC drops to 250/mcL, platelets drop to 12,000/mcL). The patient also exhibits acute memory loss, confusion, and low-grade fevers. Which viral pathogen is the most likely cause of this secondary graft failure and encephalitis?
A patient with acute myeloid leukemia (AML) who is 90 days post-allogeneic transplant undergoes routine surveillance testing. Lineage-specific STR-PCR chimerism shows that CD3+ T-cell donor chimerism has decreased from 100% to 80%, and CD33+ myeloid donor chimerism has dropped from 100% to 70%. The patient is currently asymptomatic with normal peripheral counts. What is the clinical significance of these findings and the recommended first intervention?